RTTNews | Aug 30, 2021 09:22AM EDT

09:21 Monday, August 30, 2021 (RTTNews.com) - Clinical-stage biopharmaceutical company Lantern Pharma (LTRN) said the FDA has granted LP-184 Orphan Drug Designation for the treatment of glioblastoma multiforme and other malignant gliomas. Previously, LP-184 was granted Orphan Drug Designation for the treatment of pancreatic cancer.

LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways.

Shares of Lantern Pharma were up 5% in pre-market trade on Monday.

Read the original article on RTTNews ( https://www.rttnews.com/3221855/lantern-pharma-fda-grants-additional-orphan-drug-designation-for-lp-184-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved